Latest Special Dividends News

Big moves came from disclosure drama, CEO change news, and one standout software upgrade. While several stocks jumped on results, a few gaps couldn’t hold as traders sold into early strength.

ECP Emerging Growth Limited reported a 6.9% portfolio loss for H1 2025, underperforming the ASX Small Ordinaries Index, yet declared a fully franked interim dividend and teased a significant special dividend.

South32 Limited reported a 29% rise in profit for the half year ended December 2025, driven by higher base and precious metals prices and solid operational performance. The company declared a fully-franked interim dividend and maintained its FY26 production guidance, while advancing key projects and managing portfolio transitions.

Bravura Solutions has delivered a robust first half of FY26, posting nearly 10% revenue growth and a significant jump in profitability, while rewarding shareholders with a special dividend. The company also upgraded its full-year guidance, signalling confidence in its growth trajectory.

Bravura Solutions reports robust half-year growth with nearly 10% revenue increase, a fresh leadership appointment, and strategic expansion into the UK pensions market.

Bravura Solutions reported a solid 9.8% increase in underlying revenue for the half-year ending December 2025, despite the absence of prior non-recurring licence sale income. The company also announced a new CEO appointment and declared both interim and special dividends.

Future Generation Global Limited has announced a fully franked special dividend of AUD 0.03 per share for the half-year ending December 2025, accompanied by a dividend reinvestment plan with no discount.

Australian Foundation Investment Company Limited has updated its interim and special dividend details, including foreign currency exchange rates and pricing for its Dividend Reinvestment and Substitution Share Plans.

Future Generation Global Limited has announced a substantial 49% increase in its fully franked dividend for FY2025, alongside a special dividend, reflecting robust portfolio performance and a commitment to shareholder returns.

A single diagnostics update sparked a breakout week, while a handful of biotech names sold off hard despite busy newsflow. Capital raisings, takeover steps and US market pushes kept healthcare in motion heading into mid-February milestones.

Apiam Animal Health has secured court approval for its corporate scheme, paving the way for a fully franked special dividend payment next month.

Apiam Animal Health’s acquisition scheme by Adamantem Capital has been legally approved, leading to the suspension of its shares on the ASX. Key dates for dividend payments and scheme implementation are now set.